MARLBOROUGH, Mass. - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology firm, has announced the presentation of new preclinical data on its proprietary INTASYL siRNA gene silencing technology at the 10th Immunotherapy of Cancer Conference (ITOC10) in Munich, Germany. The data, unveiled today, focuses on the potential of INTASYL Compound PH-905 to enhance the effectiveness of natural killer (NK) cells in fighting cancer.
The preclinical study demonstrated that INTASYL, targeting a gene known as Cbl-b, could silence its mRNA without affecting the viability of NK cells. This silencing resulted in increased proliferation and cytotoxicity of these cells against Chronic Myelogenous Leukemia (CML) cells. The compound also improved NK cell fitness, indicated by the upregulation of CD98 and CD25, which may enhance NK metabolism and activation in response to interleukin-2 (IL-2).
Phio's President and CEO, Robert Bitterman, highlighted the versatility of INTASYL technology in potentially improving Adoptive Cell Therapy (ACT) for hematological malignancies. The company aims to leverage this technology to develop more effective cancer treatments.
The poster presented at ITOC10, titled "Enhancing NK cell cytotoxicity against tumor cells with a novel self-delivering RNAi compound targeting Cbl-b," provided details on the increased functional cytotoxicity of NK cells towards tumor cells after Cbl-b silencing. The research suggests that INTASYL Compound PH-905 could be used to improve the anti-tumor response of NK cells, offering a new avenue for cancer therapy.
Phio Pharmaceuticals, known for its focus on immuno-oncology therapeutics, designs its INTASYL technology to target specific proteins that hinder the body's ability to fight cancer. The company's approach does not require specialized formulations or drug delivery systems, setting it apart in the field of gene silencing.
The information presented is based on a press release statement and is intended for informational purposes only. It does not constitute an endorsement of the company or its technology. Investors and interested parties are advised to consider the inherent uncertainties and risks associated with the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.